I am the Surgical Lead and a Trial Management Group member for this innovative study sponsored by the Institute of Cancer Research. This trial will look at the use of novel targeted treatments in women who have not fully responded to chemotherapy given before breast surgery, and is trialling some novel agents. I have been involved in the study since its inception, and continue to provide surgical expertise in design, protocol development and oversight of this study, which is commercially funded by AstraZeneca.